Literature DB >> 6761908

Comparison of in vitro pyrimethamine assays and in vivo response to sulphadoxine-pyrimethamine in Plasmodium falciparum from Papua New Guinea.

G Lamont, B Darlow.   

Abstract

The in vitro pyrimethamine sensitivity of 20 Plasmodium falciparum isolates from Papua New Guinea children was determined. The children were treated with sulphadoxine-pyrimethamine and six were found to have clinically resistant malaria. The P. falciparum isolated from these subjects were more resistant to pyrimethamine in vitro than 13 of the isolates from sensitive cases. These results suggest that pyrimethamine sensitivity alone may be a good indicator of in vitro response to sulphadoxine-pyrimethamine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6761908     DOI: 10.1016/0035-9203(82)90111-0

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  4 in total

1.  In vitro sensitivity of southern African reference isolates of Plasmodium falciparum to chloroquine and pyrimethamine.

Authors:  J A Freese; M B Markus; J Golenser
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

2.  Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.

Authors:  M D Edstein; K H Rieckmann; J R Veenendaal
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya.

Authors:  H C Spencer; W M Watkins; D G Sixsmith; D K Koech; J D Chulay
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

4.  Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria.

Authors:  D Botero; M Restrepo; A Montoya
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.